Like the previous version, the new (unified) GastroPanel is a quantitative ELISA test panel that measures the blood plasma concentrations of four stomach-specific biomarkers: pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17) and Helicobacter pylori IgG antibodies. In the new test version, all four biomarkers are processed under uniform reaction conditions and using common reagents, increasing its acceptance among users, while making the test less labour-intense and reducing the overall processing time. The main indications for use of the GastroPanel remain unchanged. The test is designed for the diagnosis of (1) H. pylori infection (2) atrophic gastritis (AG), and (3) functional disorders among symptomatic (dyspeptic) patients as well as for screening of asymptomatic subjects for gastric cancer risk. Also, the interpretation algorithm has been revised, and is now based on 8 distinct biomarker profiles, 5 of them reflecting morphological abnormalities and 3 others a functional disorder. <\/p>\n
\nSupplier:<\/strong> Biohit Oyj
\nWebsite:<\/strong> <\/a><\/p>\n